Muutke küpsiste eelistusi

E-raamat: Inflammatory Bowel Disease: Basic Research, Clinical Implications and Trends in Therapy

Edited by , Edited by , Edited by , Edited by , Edited by
  • Formaat: PDF+DRM
  • Ilmumisaeg: 06-Dec-2012
  • Kirjastus: Springer
  • Keel: eng
  • ISBN-13: 9789400903715
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 55,56 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Inflammatory Bowel Disease: Basic Research, Clinical Implications and Trends in TherapySuurem pilt
  • Formaat: PDF+DRM
  • Ilmumisaeg: 06-Dec-2012
  • Kirjastus: Springer
  • Keel: eng
  • ISBN-13: 9789400903715
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

The inflammatory bowel diseases, of unknown etiology and for which there are no cures, continue to attract the attention and interest of gastroenterologists, internists and surgeons. International symposia are common and it is safe to say that there is at least one major symposium held somewhere in the world each year. This book encompasses the proceedings of two recent symposia held in Victoria, British Columbia, Canada. The symposia were the fifth and sixth international meetings focused on inflammatory bowel disease in Canada in the last eight years. Once again they were sponsored by Axcan Pharma, Inc. (formerly Interfalk Canada, Inc.) and endorsed by the Canadian Association of Gastroenterology. As has become traditional at such meetings the faculty was drawn from an international roster ofleaders in the field of inflammatory bowel disease and gastroenterology. The chapters of the proceedings provide a timely, up-to-date review of the major issues, including those within the realm of basic science and others dealing with clinical problems. The first symposium, 'Basic Research and Clinical Implications', was co-ordinated by John Wallace in association with Stephen Collins and Stephan Targan. The themes of this section were organized under the general topics of predisposing factors (genetics, animal models, infection, permeability, and immune deficits) and the pathophysiology of intestinal inflammation. The second symposium, Trends in Therapy' was organized by Lloyd Sutherland along with Franc;:ois Martin, Robin McLeod and Noel Williams.

Muu info

Springer Book Archives
1: Basic Research and Clinical Implications in IBD.- Section I:
Predisposing Factors in the Etiology of IBD: What We Can Learn from Animal
Models.- 1 Subclinical markers of human IBD.- 2 Genetic factors in animal
models of intestinal inflammation.- 3 Multifactorial control of autoimmune
insulin-dependent diabetes in NOD mice: lessons for inflammatory bowel
disease.- 4 Genetics of complex diseases: from mouse to man and back.-
Section II: Predisposing Factors in the Etiology of IBD: Bugs, Drugs and
Leaks.- 5 Crohns disease: the pathogenesis of a granulomatous vasculitis: a
hypothesis.- 6 Intestinal permeability: the basics.- Section III:
Predisposing Factors in the Etiology of IBD: Is There a Primary Immune
Defect?.- 7 Etiology of organ-specific autoimmunity.- 8 Regulation of mucosal
immune responses the missing link in IBD?.- 9 T cell repertoire and IBD.-
10 On the pathogenesis trail: what marker B cell clones tell us about IBD.-
Section IV: Pathophysiology of Intestinal Inflammation: Intracellular and
Intercellular Signalling.- 11 Growth factors in IBD.- 12 Nitric oxide and
chronic colitis.- Section V: Pathophysiology of Intestinal Inflammation:
Symptom Generation In IBD.- 13 Cytokine interactions with epithelium.- 14
Immunomodulation of epithelium.- 15 The enteric nervous system in intestinal
inflammation.- 16 The role of smooth muscle in intestinal inflammation.- 17
Braingut interactions in IBD: mechanisms of anorexia in animal models of
experimental colitis.- 2: Trends in IBD Therapy 1994.- Section VI: Critical
Appraisal of Clinical Trials.- 18 How to critically appraise a clinical
trial.- 19 Finding the right index for IBD.- 20 Special problems associated
with surgical trials in IBD.- 21 Trends in IBD therapy: a meta-analytic
approach.- Section VII: BasicScience: Genetics, Markers and Models.- 22 New
IBD markers: definition of disease heterogeneity.- 23 Lessons in IBD
pathogenesis from new animal models of spontaneous colitis.- 24 Potential
human models of IBD.- Section VIII: Basic Science: Pathogenesis.- 25 New
concepts of pathogenesis in IBD.- 26 The gutbrain axis in IBD: an
investigators perspective.- 27 Gutbrain interactions in IBD: a clinicians
perspective.- Section IX: Surgical Issues in IBD.- 28 Cancer risk in IBD.- 29
Management of stomal complications.- 30 Indications and contraindications to
reconstructive surgery in ulcerative colitis.- 31 Pouchitis whats new in
etiology and management?.- 32 Laparoscopic techniques: what is the role in
IBD?.- Section X: Lifestyle in IBD.- 33 Smoking.- 34 Nutritional advice.- 35
IBD, the oral contraceptive pill and pregnancy.- 36 The social toll of IBD.-
37 Insurance rating of patients with IBD: a report of a conference on
morbidity and mortality.- Section XI: Therapeutics.- 38 Overview of 5-ASA in
the therapy of IBD.- 39 Immunosuppressive agents in IBD: current status and
future prospects.- 40 Novel targets for anti-inflammatory therapy in IBD.-
Section XII: Therapy in IBD in 1994.- 41 A gastroenterologists perspective
of the medical management of patients with Crohns disease and ulcerative
colitis.- 42 Therapy of IBD in 1994: a surgeons perspective.
Lisainfo e-raamatute kohta Lisainfo e-raamatute kohta
Püsilink: https://www.kriso.ee/db/97894009037152e.html
Märksõnad: